Michael J. Rogers

29.3k total citations · 8 hit papers
258 papers, 21.6k citations indexed

About

Michael J. Rogers is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michael J. Rogers has authored 258 papers receiving a total of 21.6k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Molecular Biology, 123 papers in Oncology and 55 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michael J. Rogers's work include Bone health and treatments (112 papers), Bone Metabolism and Diseases (39 papers) and Radiopharmaceutical Chemistry and Applications (36 papers). Michael J. Rogers is often cited by papers focused on Bone health and treatments (112 papers), Bone Metabolism and Diseases (39 papers) and Radiopharmaceutical Chemistry and Applications (36 papers). Michael J. Rogers collaborates with scholars based in United States, United Kingdom and Finland. Michael J. Rogers's co-authors include R.G.G. Russell, Fraser P. Coxon, Frank H. Ebetino, Jukka Mönkkönen, Steven P. Luckman, Keith Thompson, Julie C. Frith, Philipp Strittmatter, Helena L. Benford and Sharon Gordon and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Michael J. Rogers

255 papers receiving 20.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy

2008 1.1k citations R.G.G. Russell, Frank H. Ebetino et al. profile →
Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras

1998 977 citations D. E. Hughes, Fraser P. Coxon et al. Journal of Bone and Mineral Research profile →
Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates

2001 726 citations James E. Dunford, Fraser P. Coxon et al. profile →
Cellular and molecular mechanisms of action of bisphosphonates

2000 720 citations Michael J. Rogers, Helena L. Benford et al. profile →
Bisphosphonates: from the laboratory to the clinic and back again

1999 677 citations R.G.G. Russell, Michael J. Rogers Bone profile →
Cellular and molecular mechanisms of action of bisphosphonates

2000 571 citations Michael J. Rogers, Helena L. Benford et al. profile →
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

1999 570 citations Michael J. Rogers, R.G.G. Russell et al. profile →
Purification and Properties of Rat Liver Microsomal Stearyl Coenzyme A Desaturase

1974 379 citations Michael J. Rogers et al. profile →

Peers

Countries citing papers authored by Michael J. Rogers

Since Specialization

Citations

This map shows the geographic impact of Michael J. Rogers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Rogers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Rogers more than expected).

Fields of papers citing papers by Michael J. Rogers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Rogers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Rogers. The network helps show where Michael J. Rogers may publish in the future.

Co-authorship network of co-authors of Michael J. Rogers

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Rogers. A scholar is included among the top collaborators of Michael J. Rogers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Rogers. Michael J. Rogers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 12914: Effect of Home-Based versus Center-Based Cardiac Rehabilitation Among Attendees From a Large Healthcare System During the Covid-19 Pandemic 2022 ·Circulation ·(unknown), (unknown), (unknown), Amanda R. Bonikowske, (unknown), Michael J. Rogers, (unknown), (unknown), Robert Scales, (unknown), Joshua R. Smith, (unknown), Bryan J. Taylor, Courtney M. Wheatley, Thomas P. Olson	0
2	Increased core body temperature exacerbates defective protein prenylation in mouse models of mevalonate kinase deficiency 2022 ·Journal of Clinical Investigation ·Marcia A. Munoz, (unknown), Etienne Masle‐Farquhar, Julie Jurczyluk, Ya Xiao, (unknown), (unknown), Mark P. Hodson, Séan O’Donoghue, Sandeep Kaur, Robert Brink, (unknown), Elissa K. Deenick, (unknown), Avril A. B. Robertson, Sam Mehr, Pravin Hissaria, Catharina M. Mulders‐Manders, Anna Simon, Michael J. Rogers	4
3	Oxysterols: From physiological tuners to pharmacological opportunities 2020 ·British Journal of Pharmacology ·Andrew J. Brown, Laura J. Sharpe, Michael J. Rogers	62
4	Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer 2014 ·Cancer Discovery ·Simon Junankar, Gemma Shay, Julie Jurczyluk, Naveid Ali, Jenny Down, Nicholas Pocock, Andrew Parker, Akira Nguyen, Shuting Sun, B. A. Kashemirov, Charles E. McKenna, Peter I. Croucher, Alexander Swarbrick, Katherine N. Weilbaecher, Tri Giang Phan, Michael J. Rogers	119
5	The regulation of osteoclast function and bone resorption by small GTPases 2011 ·Small GTPases ·Cécile Itzstein, Fraser P. Coxon, Michael J. Rogers	119
6	Lowering Bone Mineral Affinity of Bisphosphonates as a Therapeutic Strategy to Optimize Skeletal Tumor Growth Inhibition In vivo 2008 ·Cancer Research ·Pierrick G.J. Fournier, Florence Daubiné, Mark W. Lundy, Michael J. Rogers, Frank H. Ebetino, Philippe Clézardin	36
7	Phosphonocarboxylates Inhibit the Second Geranylgeranyl Addition by Rab Geranylgeranyl Transferase 2008 ·Journal of Biological Chemistry ·Rudi Baron, Richard Tavaré, Ana C. Figueiredo, K. M. Błażewska, B. A. Kashemirov, Charles E. McKenna, Frank H. Ebetino, Adam Taylor, Michael J. Rogers, Fraser P. Coxon, Miguel C. Seabra	46
8	Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells 2008 ·Journal of Cellular and Molecular Medicine ·Benjamin Ory, Gatien Moriceau, Valérie Trichet, Frédéric Blanchard, Martine Berreur, Françoise Rédiní, Michael J. Rogers, Dominique Heymann	27
9	Kinetic analysis of conformational changes in farnesyl pyrophosphate synthase induced by nitrogen containing bisphosphonates 2007 ·Calcified Tissue International ·James E. Dunford, K.L. Kavanagh, Michael J. Rogers, Udo Oppermann, (unknown), R.G.G. Russell	3
10	Polymorphic variation in the FPP synthase (FPPS) gene and effects on bisphosphonate inhibition 2007 ·Journal of Bone and Mineral Research ·(unknown), Fiona E. McGuigan, James E. Dunford, (unknown), Michael J. Rogers	1
11	Nitrogen-containing bisphosphonates of varying antiresorptive potency have been co-crystallized in farnesyl diphosphate synthase and modelled to understand the key structural features involved in enzyme inhibition. 2006 ·Journal of Bone and Mineral Research ·Frank H. Ebetino, B.L. Barnett, (unknown), B. A. Kashemirov, Charles E. McKenna, A.G. Evdokimov, Matthew Pokross, James E. Dunford, (unknown), K.L. Kavanagh, Michael J. Rogers, R.G.G. Russell	1
12	Studies to elucidate the anti-tumor mechanism of action of risedronate in human myeloma cells; Use of an analogue of risedronate reveals the effects of differential inhibition of prenylation 2005 ·Cancer Treatment Reviews ·Anke J. Roelofs, P A Hulley, R.G.G. Russell, Frank H. Ebetino, Michael J. Rogers	1
13	The mechanism of inhibition of farnesyl diphosphate synthase by nitrogen-containing bisphosphonates 2002 ·Bone ·James E. Dunford, Frank H. Ebetino, Michael J. Rogers	5
14	Identification of a Novel Phosphonocarboxylate Inhibitor of Rab Geranylgeranyl Transferase That Specifically Prevents Rab Prenylation in Osteoclasts and Macrophages 2001 ·Journal of Biological Chemistry ·Fraser P. Coxon, Miep Helfrich, Banafshé Larijani, M Muzylak, James E. Dunford, Deborah Marshall, Alastair McKinnon, Stephen A. Nesbitt, Michael A. Horton, Miguel C. Seabra, Frank H. Ebetino, Michael J. Rogers	136
15	The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma 2000 ·British Journal of Haematology ·C M Shipman, Karin Vanderkerken, Michael J. Rogers, J M Lippitt, Kewal Asosingh, D. E. Hughes, (unknown), R.G.G. Russell, Peter I. Croucher	25
16	Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite 1999 ·European Journal of Pharmaceutical Sciences ·(unknown), Antero Salminen, Michael J. Rogers, Julie C. Frith, Arto Urtti, Elena Azhayeva, Jukka Mönkkönen	88
17	Farnesol and Geranylgeraniol Prevent Activation of Caspases by Aminobisphosphonates: Biochemical Evidence for Two Distinct Pharmacological Classes of Bisphosphonate Drugs 1999 ·Molecular Pharmacology ·Helena L. Benford, Julie C. Frith, Seppo Auriola, Jukka Mönkkönen, Michael J. Rogers	5
18	Introduction to bisphosphonates and the clinical pharmacology of alendronate 1997 ·Lara D. Veeken ·R.G.G. Russell, Michael J. Rogers	12
19	Competition of aminoacyl-tRNA synthetases for tRNA ensures the accuracy of aminoacylation 1992 ·Nucleic Acids Research ·Joyce M. Sherman, Michael J. Rogers, Dieter Söll	47
20	Tumor-associated transplantation antigens of chemically-induced tumors: new complexities 1984 ·Immunology Today ·Michael J. Rogers	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact